RenovoRx, Inc. (RNXT) has a negative trailing P/E of -3.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 14.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -32.55%, forward earnings yield 6.80%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -32.8 | 0.00 | 85.85 | 0.00 | - |
| 2020 | -33.1 | -2.43 | -8.58 | 0.00 | - |
| 2021 | -13.7 | -0.23 | 5.63 | 0.00 | - |
| 2022 | -4.3 | -0.12 | 6.90 | 0.00 | - |
| 2023 | -4.6 | 0.62 | -15.71 | 0.00 | - |
| 2024 | -3.5 | 0.13 | 6.80 | 708.18 | - |
| 2025 | -2.7 | 0.20 | 5.47 | 26.43 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.22 | $0.00 | $-3.78M | - |
| 2020 | $-0.25 | $0.00 | $-4.39M | - |
| 2021 | $-0.40 | $0.00 | $-7.1M | - |
| 2022 | $-0.54 | $0.00 | $-9.77M | - |
| 2023 | $-0.50 | $0.00 | $-10.23M | - |
| 2024 | $-0.40 | $43K | $-8.81M | -20497.7% |
| 2025 | $-0.32 | $1.12M | $-11.17M | -994.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.22 | $-0.24 – $-0.19 | $4.17M | $3.91M – $4.43M | 1 |
| 2027 | $-0.05 | $-0.06 – $-0.04 | $16.53M | $13.58M – $20.22M | 2 |
| 2028 | $0.11 | $-0.27 – $0.35 | $38.33M | $38.31M – $38.36M | 3 |
| 2029 | $0.74 | $0.57 – $0.95 | $123.95M | $101.8M – $151.58M | 1 |
| 2030 | $2.36 | $1.81 – $3.04 | $353.89M | $290.67M – $432.79M | 1 |
